Drug Profile
Research programme: cancer therapeutics - Crescendo Biologics/Takeda
Alternative Names: Humabody® drug conjugates - Crescendo Biologics/TakedaLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Crescendo Biologics
- Developer Crescendo Biologics; Takeda Oncology
- Class Antineoplastics; Drug conjugates; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Oct 2023 Preclinical development is ongoing in Cancer in USA (Parenteral) (Crescendo Biologics pipeline, October 2023)
- 29 Dec 2020 The anti-cancer therapeutics programme is still in preclinical development (Crescendo Biologics pipeline, December 2020)
- 11 Dec 2020 Crescendo Biologics expands its global, multi-target discovery and development collaboration with Takeda